Evonik and Fuhua complete Leshan specialty H2O2 plant

Key highlights
  • Evonik Fuhua New Materials completed construction of a specialty hydrogen peroxide (H2O2) plant in Leshan, Sichuan.
  • The plant is entering trial production, with full start-up expected in Q2 2026.
  • Annual production capacity is 20,000 tonnes of specialty H2O2.
  • It will purify industrial-grade H2O2 into specialty grades for photovoltaics, semiconductors, food packaging, cosmetics and pharmaceuticals.

Project status

Construction of the specialty hydrogen peroxide (H2O2) plant in Leshan, Sichuan has been completed and the facility is entering trial production.

Timeline and capacity

First commercial volumes are expected in Q2 2026 with an annual production capacity of 20,000 tonnes.

Technology and feedstock

The plant uses technology licensed from Evonik’s Active Oxygens business and purifies industrial‑grade H2O2 supplied by Fuhua into specialty grades.

Target applications

Produced specialty grades are intended for photovoltaics, semiconductors, food packaging, cosmetics and pharmaceuticals.

Source: Evonik

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

30 July 2026
Evonik‑licensed Leshan H₂O₂ megaplant (Fuhua) starts production

200 kt/yr industrial H₂O₂ plant began operations on 18 June 2026; will sell to the merchant market and supply a JV for further purification into specialty grades.

10 June 2026
Evonik opens pilot plant for high-performance AEM membrane

Pilot-scale polymer membrane production for AEM electrolysis targets up to 2.5 GW/year, enabling lower-cost green hydrogen and manufactured without PFAS.

11 June 2026
Evonik launches low‑carbon peracetic acid for Europe

Peracetic acid produced using bio-based acetic acid and low‑carbon hydrogen peroxide; mass‑balance accounting lets customers lower Scope 3 emissions transparently.

1 August 2025
Evonik Reports Q2 Demand Decline

Q2 2025 saw a 12% EBITDA drop due to weak demand, currency effects, and divestments. Revenue fell 11%. Fewer shutdowns and new capacities expected to aid H2.